Adlai Nortye (ANL) Liabilities and Shareholders Equity (2022 - 2025)
Adlai Nortye (ANL) reported Liabilities and Shareholders Equity of $34.4 million for Q4 2025, down 51.69% year-over-year from $71.3 million in Q4 2024, and down 52.21% on a QoQ basis from $72.0 million in Q2 2025.
Adlai Nortye (ANL) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $34.4 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 51.69% year-over-year to $34.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $285.4 million (down 25.23% YoY) and the FY2025 annual result came in at $34.4 million, down 51.69% from the prior year.
- Liabilities and Shareholders Equity retreated to $34.4 million in Q4 2025 per ANL's latest filing, from $72.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $130.2 million in Q4 2023 and bottomed at $34.4 million in Q4 2025.
- The 4-year median for Liabilities and Shareholders Equity is $72.3 million (2022), against an average of $81.4 million.
- The widest annual swing landed in 2023, when Liabilities and Shareholders Equity soared 79.34%; it then tumbled 51.69% in 2025.
- Tracing ANL's Liabilities and Shareholders Equity over 4 years: stood at $72.6 million in 2022, then surged by 79.34% to $130.2 million in 2023, then sank by 45.26% to $71.3 million in 2024, then sank by 51.69% to $34.4 million in 2025.
- Per Business Quant, the three latest ANL Liabilities and Shareholders Equity figures stand at $34.4 million (Q4 2025), $72.0 million (Q2 2025), and $71.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | 34.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.43 Mn |
| Jun 30, 2025 | 72.05 Mn |
| Dec 31, 2024 | 71.27 Mn |
| Jun 30, 2024 | 107.68 Mn |
| Dec 31, 2023 | 130.19 Mn |
| Dec 31, 2022 | 72.59 Mn |